Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT01393808

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01393808
  • EudraCT 2011-001713-14
Other papers using this trial's data
  • Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial The lancet. Diabetes & endocrinology, 2018-01 DOI, PubMed 29104158

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01393808. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
Acronym
PROCEED
Intervention (Drug)
Paricalcitol
Intervention (Other)
placebo
Lead sponsor
Mario Negri Institute for Pharmacological Research (class: other)
Collaborator
Abbott (class: industry)

Record details

Record id
cardio:ct-nct01393808
Content hash
3245867dee71c8ac6dfa9680f1f74cb4d7eafe3bd9739ee315637a6f1e9e4ae4